Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

NCT04988607 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Osimertinib
DRUG: Bevacizumab
DRUG: Osimertinib

Sponsor

Guangdong Association of Clinical Trials